1. Introduction {#sec1}
===============

Weight loss in obese humans can be reliably attained by a sufficient reduction in calorie intake below that of calorie expenditure, with or without concomitant increased physical activity. However, significant weight regain over subsequent years is nearly universal [@bib1]. The inability to maintain weight loss has been attributed to multiple factors including reductions in circulating leptin, but regardless of the precise mechanism this phenomenon has prompted vigorous debate over the concept of altered body weight set point and alternatives to dieting for sustained weight loss, including bariatric surgery and an exploration of polypharmaceutical treatment approaches.

The role of leptin in human energy balance and evidence supporting its major function to signal negative energy balance when levels are low has been reviewed comprehensively by Rosenbaum and Leibel [@bib2]. Many clinical studies [@bib3], [@bib4], [@bib5], [@bib6], [@bib7], [@bib8], but not all [@bib9], support the conclusion that weight loss induced by dieting results in reduced circulating leptin associated with decreased satiation and lower than predicted metabolic rate that, at least in part, contribute to the high recidivism rate for weight regain. Although it is well established that leptin treatment is not an effective measure to induce weight loss in patients with common obesity, it may be beneficial in helping to maintain established weight loss following dieting [@bib2] and recent studies suggest that leptin sensitizing agents may be key to employing leptin pharmacotherapy [@bib10].

Diet-induced obesity (DIO) in mice has been employed frequently as a model with high face value for polygenic obesity in humans. DIO C57BL/6J mice switched to low fat chow exhibit significant weight loss but eventually defend a higher body weight and adiposity index than control mice that never were exposed to the high fat diet [@bib11]. This elevated body weight set point may be due to relative hypometabolism, as found in humans, based on indirect calorimetry measurements [@bib12]. Furthermore, DIO mice whose body weight is reduced to that of control mice by calorie restriction regain more weight when subsequently provided ad libitum access to low fat chow than those pair-fed to control mice that had always been fed low fat chow [@bib13]. Another study using DIO C57BL/6J mice, with or without calorie restriction to reduce their body weight below that of sham controls prior to Roux-En-Y gastric bypass (RYGB) surgery, provides evidence for bidirectional defense of body weight set point [@bib14]. Although the precise physiological mechanism was not determined, the final settling points for body weight and adiposity index were strongly correlated with pre-surgical values of the same parameters in each mouse. The previously obese mice that were calorie restricted prior to RYGB surgery actually regained weight and fat mass to final levels that were almost the same as those of the DIO mice without calorie restriction. Chronic hyperleptinemia, per se, associated with DIO adiposity does not appear to explain elevated body weight set point because the same phenomenon did not occur in mice fed a low fat diet and chronically infused with leptin to mimic the high endogenous leptin levels of DIO mice [@bib15]. A caveat with use of the DIO mouse model to study the mechanisms regulating body weight set point, and in particular the role of altered leptin levels [@bib15], is the chronic inflammatory state induced in the liver, adipose tissue and hypothalamus by an excess of fatty acids in the diet [@bib13], [@bib16].

Our laboratory has recently developed an alternative genetic model of obesity in mice fed a standard low fat chow that is based on the conditionally reversible silencing of proopiomelanocortin (*Pomc*) gene expression in the arcuate nucleus of the hypothalamus (Arc*Pomc*^−/−^) [@bib17]. POMC regulates energy balance primarily by controlling feeding behavior and energy expenditure [@bib17], [@bib18]. These effects are largely mediated by POMC-derived melanocortin peptides that are agonists for central melanocortin (MC) 3 and/or 4 receptors, see for review [@bib19]. Consequently, Arc*Pomc*-deficiency causes obesity associated with extreme hyperleptinemia by a combination of hyperphagia, reduced locomotor activity and decreased energy expenditure.

Central MC3 and/or 4 receptor signaling is involved in mediating the effects of leptin on energy balance [@bib20], [@bib21], [@bib22], [@bib23], [@bib24], [@bib25]. The actions of leptin to reduce body weight and food intake [@bib26], [@bib27] are attenuated in a genetic model of *Mc4r*^−/−^ mice [@bib28], [@bib29] and in a pharmacological model of rats treated with the MC3/4 antagonist SHU9119 [@bib30], indicating the importance of the melanocortin system in mediating these functions of leptin. Hypothalamic *Pomc* expression is upregulated by leptin and reduced in leptin-deficient (*ob*/*ob*) or leptin receptor-deficient (*db*/*db*) mice [@bib31]. Additionally, restoration of Arc*Pomc* in the leptin receptor-expressing sub-population of hypothalamic POMC neurons was sufficient to normalize energy balance in otherwise Arc*Pomc*^−/−^ mice [@bib32], further supporting an important interaction of Arc*Pomc* and leptin signaling. Moreover, leptin activates POMC neurons to secrete anorexigenic peptides and inhibits NPY/AgRP neurons to attenuate the release of orexigenic signals [@bib33].

We demonstrated previously that genetic restoration of Arc*Pomc* expression at postnatal day 25 prevented excessive weight gain in the obesity-programmed Arc*Pomc*^−/−^ mice [@bib17]. However, Arc*Pomc* reactivation in older and massively obese mice failed to fully reverse the established obesity phenotype and accompanying metabolic disturbances. In the current study, we hypothesized that leptin- and POMC-mediated control of energy homeostasis are reciprocally linked to each other and that reducing the body weight of obese, hyperleptinemic Arc*Pomc*^−/−^ adult mice by calorie restriction prior to reactivation of *Pomc* expression would restore their body weight set point to that of lean control mice of the same age. Therefore, we measured plasma leptin levels, leptin sensitivity, and body composition in Arc*Pomc*^−/−^ mice at different ages and under prolonged conditions of ad libitum access to chow or calorie restriction. Moreover, we performed a longitudinal study in calorie restricted Arc*Pomc*^−/−^ mice treated with a novel long acting version of leptin using PASylation technology [@bib34], [@bib35] to mimic the hyperleptinemia of obese Arc*Pomc*^−/−^ mice and better understand the association of leptin sensitivity and the central melanocortin system in regulating energy balance.

2. Methods {#sec2}
==========

2.1. Animal husbandry {#sec2.1}
---------------------

All animal procedures were approved by the University of Michigan\'s Institutional Animal Care and Use Committee and followed the National Research Council\'s "Guide for the Care and Use of Laboratory Animals." Mice of mixed genotypes derived from Arc*Pomc*^+/−^ breeding pairs that had been back-crossed onto the C57BL/6J background for \>12 generations were group housed in ventilated cages on corn cob bedding under controlled temperature (22 °C) and photoperiod (12 h light/12 h dark cycle, lights on from 6 a.m. to 6 p.m.), with tap water and standard laboratory chow (LabDiet, 5L0D; containing 28.5 kcal% protein, 13.5 kcal% fat, and 58.0 kcal% carbohydrate) available ad libitum. Mice were housed individually for studies involving weight-matching by calorie restriction.

2.2. Generation and breeding of mice {#sec2.2}
------------------------------------

Compound Arc*Pomc*^*−*/*−*^;*Pomc*-Cre-ERT2 and their corresponding control mice were generated by crossing Arc*Pomc*^+/−^ mice with BAC transgenic *Pomc*-Cre-ERT2 mice [@bib36] (gift from Dr. Joel Elmquist, UT Southwestern Medical Center) followed by a second generation of intercrossing between the resulting compound double heterozygous mice and Arc*Pomc*^+/−^ mice. Arc*Pomc*^−/−^ mice contain a loxP-flanked neomycin resistance cassette, inserted in the neuronal enhancer locus of the *Pomc* gene, that selectively blocks *Pomc* transcription in Arc hypothalamic neurons [@bib17], [@bib18]. After tamoxifen administration, the *Pomc*-Cre-ERT2 transgene specifically and effectively removed the loxP-flanked STOP sequence from the Ai9 reporter allele (B6.Cg-*Gt(ROSA)26Sor*^*tm9(CAG-tdTomato)Hze*^/J; The Jackson Laboratory) as demonstrated by co-localization of red fluorescence in 80--90% of immunohistochemically labeled POMC neurons in the arcuate nucleus (unpublished results). The *Pomc*-Cre-ERT2 and *CAG*-Cre-ERT transgenes yielded equivalent tamoxifen induced deletion of the loxP-flanked neomycin cassette from the targeted Arc*Pomc*^*−*/*−*^ alleles, and hence reactivation of *Pomc* expression in the Arc. However, the Arc*Pomc*^*−*/*−*^;*Pomc*-Cre-ERT2 compound mice had better breeding efficiency than the Arc*Pomc*^+/*−*^;*CAG*-Cre-ERT mice and therefore were used for the majority of experiments.

2.3. Calorie restriction procedure {#sec2.3}
----------------------------------

Individually housed Arc*Pomc*^*−*/*−*^ mice were fed 75--80% of the average amount of chow consumed daily by their control littermates starting at age 25-days, shortly after weaning, to continuously match body weights between the two genotypes up to age 16-wk. For these and the following studies, the daily allotment of chow was provided 1 h before lights out.

For the longitudinal studies, compound Arc*Pomc*^*−*/*−*^;*Pomc*-Cre-ERT2 or Arc*Pomc*^−/−^;*CAG*-Cre-ERT mice with free access to chow were allowed to become obese until their body weights stabilized at 5--6 months of age. The obese mutant mice were subsequently fed 55--60% of the average amount of food consumed daily by their respective control (Arc*Pomc*^+/+^;Cre-ERT transgenic) littermates. It took 8 wk for male and 12 wk for female Arc*Pomc*^*−*/*−*^ mice on this calorie restriction protocol to reduce their body weights to match that of their sex- and age-matched controls. Thereafter, the weight-matched mutant mice and their controls received tamoxifen (50 mg/kg, ip) for each of five consecutive days as described previously [@bib17] during which time the mutant mice were maintained on their calorie restricted diet. Following the last tamoxifen injection, all mice had ad libitum access to chow until they were approximately one-year old at the conclusion of the studies.

2.4. General procedures {#sec2.4}
-----------------------

Intracerebroventricular (icv) cannulae (Plastics One) were placed into the left lateral ventricle and osmotic mini-pumps (Alzet) were implanted subcutaneously (sc) as described previously [@bib37]. Body composition was measured by NMR using a Minispec LF90II instrument (Bruker Optics). Oral glucose tolerance tests were performed as described previously [@bib37].

2.5. Leptin treatment {#sec2.5}
---------------------

For acute experiments, recombinant mouse leptin (National Hormone and Peptide Program) was injected either ip (5 mg/kg in PBS, repeated at 8 h intervals for a total of 3 doses) or icv (2 μg in 2 μl PBS, repeated at 8 h intervals for a total of 3 doses) as described previously [@bib37]. For chronic experiments, leptin was administered by osmotic mini-pumps (10 μg/day sc) for 14 days. PASylated leptin [@bib34], [@bib35] (10 mg/kg in PBS) was administered sc at 72 h intervals starting one week prior to tamoxifen injections and ending 72 h after the last tamoxifen dose.

2.6. Leptin and insulin assays {#sec2.6}
------------------------------

Plasma leptin and insulin levels were measured by ELISAs following the manufacturers\' instructions (R&D Systems, MOB00; Crystal Chem, 90080, respectively). PASylated leptin, rather than the standard leptin included in the ELISA kit, was used to construct the standard curve for analyzing plasma leptin levels during PASylated leptin administration.

2.7. Semi-quantitative real-time (qRT)-PCR {#sec2.7}
------------------------------------------

Total nucleic acid from tissue blocks was extracted using RNeasy spin columns (Qiagen) for quantification of *Lepr* or *Pomc* expression. Contaminating genomic DNA was removed by Turbo DNase treatment (Life Technologies) and total RNA was quantified using a NanoDrop spectrophotometer (ThermoScientific). Reverse transcription to generate cDNA was performed with 500 ng total RNA and random hexamer primers (Goscript RT System, Promega). qRT-PCR was performed on all samples in duplicate using a StepOne Real Time PCR System (Applied Biosystems) and SYBR Green Master Mix (Life Technologies). The primers for detection of all *Lepr* isoforms were 5′-TGGAAGGAGTTGGAAAACCA-3′ and 5′-CAGTGTTCCGAGCAGTAGGA-3′, and for specific detection of the long-form *Leprb* were 5′-GGCACAAGGACTGAATTTCC-3′ and 5′-CTGCTGGGACCATCTCATCT-3′. The primers for detection of *Pomc* were 5′-GAGCTGGTGCCTGGAGAG-3′ and 5′- TTTTCATCAGGGGCTGTTC-3′. All primers were used at a final concentration of 300 nM. The relative quantity of each mRNA was calculated from standard curves spanning 1000-fold change, normalized to the reference gene *Hprt* and then normalized to the mean of Arc*Pomc*^+/+^ controls.

2.8. Statistical analyses {#sec2.8}
-------------------------

Comparisons of one dependent variable between two independent groups were made by Student\'s unpaired t-tests while comparisons between repeated measures of one dependent variable within a single group were made by Student\'s paired t-tests. Comparisons among three or more independent groups for one dependent variable were made by one-way ANOVAs followed by Tukey\'s multiple comparisons test or Dunnett\'s multiple comparisons test for pair-wise comparisons limited to Arc*Pomc*^+/+^ controls. Comparisons among two or more independent groups for two dependent variables were made by two-way ANOVAs followed by either Sidak\'s multiple comparisons test or Dunnett\'s multiple comparisons test for pair-wise comparisons limited to Arc*Pomc*^+/+^ controls. Comparisons between two independent groups involving one dependent variable with repeated measures were made by repeated measures two-way ANOVAs (RMANOVA) followed by Bonferroni\'s multiple comparisons test. All analyses were performed separately for data from male and female mice using Prism 6.0 (Graph Pad) and *P* \< 0.05 was considered significant.

3. Results {#sec3}
==========

3.1. Increased adiposity and hyperleptinemia in juvenile Arc*Pomc*^−/−^ mice {#sec3.1}
----------------------------------------------------------------------------

We measured body composition weekly from ages 3 to 6-wk in a cohort of 35 weanlings of all three genotypes and both sexes derived from 9 litters of crosses between Arc*Pomc*^+/−^ heterozygous mice. Data from the male mice are shown in [Figure 1](#fig1){ref-type="fig"}. Arc*Pomc*^+/+^ and Arc*Pomc*^+/−^ mice were indistinguishable from each other and therefore their data were combined for statistical analysis. Two-way ANOVAs for body weight, fat mass, lean mass, percentage of fat mass relative to body mass, percentage of lean mass relative to body mass, and ratio of lean to fat mass revealed significant main effects of genotype for each dependent variable (F~1,67~ = 9.0, *P* = 0.0038; F~1,67~ = 45.4, *P* \< 0.0001; F~1,67~ = 1.8, *P* = 0.1902; F~1,67~ = 67.9, *P* \< 0.0001; F~1,67~ = 21.6, *P* \< 0.0001; and F~1,67~ = 29.0, *P* \< 0.0001, respectively) except lean mass. Post-hoc multiple comparisons tests indicated there were no significant differences between the two genotypes of mice at ages 3 and 4 wk for any of the six measures ([Figure 1](#fig1){ref-type="fig"}A--F), although trends were evident for divergent body mass and fat mass. However, by age 5-wk, all dependent variables were significantly different between genotypes, except for body mass and lean mass. The results from female mice showed similar patterns compared to males for each of the measures ([Supplemental Figure 1](#appsec1){ref-type="sec"}). Taken together, these data reveal that the earliest detected metabolic alteration of weanling Arc*Pomc*^−/−^ mice was increased adiposity that was rapidly augmented from age 5-wk onward. In contrast, body weight was only subtly elevated at age 6-wk in Arc*Pomc*^−/−^ mice.

Leptin levels from an independent cohort of 4 to 6-wk old weight-matched females were increased almost 3-fold in Arc*Pomc*^−/−^ compared to their sibling Arc*Pomc*^+/+^ mice (5.1 ± 0.7 and 1.8 ± 0.2 ng/ml, respectively, *P* \< 0.005) ([Figure 2](#fig2){ref-type="fig"}A), consistent with their altered body composition at this early age. These results suggest a direct role of hypothalamic POMC in regulating adiposity and, therefore, plasma leptin levels.

3.2. Peripheral and central leptin treatment failed to reduce body weight and food intake in weight-matched Arc*Pomc*^−/−^ mice {#sec3.2}
-------------------------------------------------------------------------------------------------------------------------------

Next, we measured plasma leptin levels and leptin sensitivity in weight-matched 8-wk old male Arc*Pomc*^−/−^ mice without any history of overweight. Following weaning, Arc*Pomc*^−/−^ mice were fed 75--80% of the average amount of chow eaten daily by their Arc*Pomc*^+/+^ littermates to constantly maintain equivalent body weights between the two genotypes. The reduced quantity of food required by Arc*Pomc*^−/−^ mice to achieve weight matching is consistent with their reduced energy expenditure compared to Arc*Pomc*^+/+^ controls [@bib17]. At age 8 wk, weight-matched Arc*Pomc*^−/−^ mice exhibited moderate hyperleptinemia with levels almost four-fold higher than their Arc*Pomc*^+/+^ controls ([Figure 2](#fig2){ref-type="fig"}B). Furthermore, after a return to ad libitum chow at age 16 wk, weight-matched Arc*Pomc*^−/−^ mice became hyperphagic and two weeks of chronic exposure to peripheral leptin treatment by sc osmotic mini-pump did not prevent further increases in their body weight ([Figure 2](#fig2){ref-type="fig"}C) or food intake ([Figure 2](#fig2){ref-type="fig"}D) in marked contrast to the reductions of both measures in control mice. In a previous study, we reported that leptin administration at a dose of 10 μg/day delivered by sc mini-pump raised circulating leptin levels of wildtype mice to ∼12 ng/ml [@bib38].

Leptin transport across the blood--brain barrier is required for its effects to decrease food intake and body weight [@bib39], [@bib40], [@bib41]. To address the possibility of decreased leptin transport into the brain of Arc*Pomc*^−/−^ mice, we tested central leptin sensitivity in a separate cohort of 8-wk old weight-matched mice using icv injection of leptin. Like peripheral leptin administration, icv leptin failed to reduce body weight and food intake in both sexes of weight-matched Arc*Pomc*^−/−^ mice ([Figure 3](#fig3){ref-type="fig"}A,B). These experiments suggest that reduced leptin transport into the brain was not the underlying cause for impaired leptin sensitivity in the Arc*Pomc*^−/−^ mice. In contrast, we previously showed that acute icv administration of the MC3/4R agonist melanotan II potently reduced food intake and bodyweight in Arc*Pomc*^−/−^ mice [@bib37], [@bib42], indicating that the fidelity of the melanocortin system downstream of the POMC neurons themselves remains intact.

3.3. Leptin receptor expression is unaltered in the hypothalami of Arc*Pomc*^−/−^ mice {#sec3.3}
--------------------------------------------------------------------------------------

Hypothalamic expression of *Lepr* total isoforms and specifically the *Leprb* isoform was normal in the mutant mice (*Lepr* mRNA: Arc*Pomc*^−/−^ mice, 84 ± 11.5 vs. control, 100 ± 8.0; *Leprb* mRNA: Arc*Pomc*^−/−^ mice, 95.5 ± 6.5 vs. control, 100 ± 5.1; data are expressed as the percentage relative to the mean of values obtained from Arc*Pomc*^+/+^ control mice). These results are in agreement with previous studies that showed normal hypothalamic *Lepr* expression despite leptin resistance in mice with diet-induced obesity [@bib43], [@bib44].

3.4. Reactivation of Arc*Pomc* expression, following weight reduction by calorie restriction, permanently normalizes body weight and food intake in previously obese mice {#sec3.4}
-------------------------------------------------------------------------------------------------------------------------------------------------------------------------

In our previous study, we found that reactivating *Pomc* expression in obese middle aged Arc*Pomc*^−/−^ mice only partially corrected their weight and metabolic disturbances [@bib17]. To further explore whether this resilience was related to a leptin resistant state, we performed a longitudinal study with repeated physiological measurements ([Figure 4](#fig4){ref-type="fig"}A). Specifically, we wanted to determine if reducing body weight, adiposity, and leptin levels in parallel by calorie restriction would improve the efficiency of genetic intervention to reverse obesity. Five to 6-month old, obese Arc*Pomc*^−/−^ mice of both sexes, with or without a Cre-ERT transgene, were calorie restricted for 8 wk (males) or 12 wk (females) to reduce their body weights to the levels of their littermate Arc*Pomc*^+/+^ controls before reactivating Arc*Pomc* expression by tamoxifen administration ([Figure 4](#fig4){ref-type="fig"}B). All mice were provided ad libitum chow access following tamoxifen treatment. We found that body weight and food intake were permanently normalized in compound Arc*Pomc*^−/−^;Cre-ERT mice due to Arc*Pomc* reactivation in the hypothalamus, while Arc*Pomc*^−/−^ mice without a Cre-ERT transgene rapidly regained weight and exhibited hyperphagia when they were provided ad libitum access to chow after tamoxifen treatment. ([Figure 4](#fig4){ref-type="fig"}C,D).

3.5. Reactivation of Arc*Pomc* in calorie restricted Arc*Pomc*^−/−^ mice restores normal energy balance {#sec3.5}
-------------------------------------------------------------------------------------------------------

We predicted that genetic reactivation of Arc*Pomc* in calorie restricted Arc*Pomc*^−/−^ mice would be associated with restoration of leptin sensitivity. To test this hypothesis, we serially measured plasma leptin and leptin sensitivity in Arc*Pomc*^−/−^ mice when they were: i) obese, ii) weight-matched by calorie restriction, and iii) following Arc*Pomc* rescue ([Figure 4](#fig4){ref-type="fig"}A). Consistent with other mouse models of severe obesity [@bib28], [@bib43], [@bib45], [@bib46], obese Arc*Pomc*^−/−^ mice had extreme hyperleptinemia ([Figure 5](#fig5){ref-type="fig"}A), and neither body weight ([Figure 5](#fig5){ref-type="fig"}B) or food intake ([Figure 5](#fig5){ref-type="fig"}C) were decreased by acute ip leptin administration. Notably, while the calorie restriction procedure was sufficient to normalize the body weight of Arc*Pomc*^−/−^ mice ([Figure 4](#fig4){ref-type="fig"}B), it did not completely reverse their hyperleptinemia and the mice remained resistant to the effects of exogenous leptin to lower body weight or food intake ([Figure 5](#fig5){ref-type="fig"}A). Their moderately elevated leptin levels were similar to those found in Arc*Pomc*^−/−^ mice that were calorie restricted following weaning to maintain normal body weight up to age 8 wk ([Figure 2](#fig2){ref-type="fig"}B). However, following reactivation of Arc*Pomc* expression in the weight reduced Arc*Pomc*^−/−^;Cre-ERT2 mice, plasma leptin levels and leptin sensitivity were restored to normal ([Figure 5](#fig5){ref-type="fig"}A,B,C).

As shown in our previous study [@bib17], the increased body weight of Arc*Pomc*^−/−^ mice was principally due to excessive accumulation of fat mass. Here, we found that calorie restriction to reduce body weight to the equivalent of their age-matched controls was insufficient to normalize adiposity in the Arc*Pomc*^−/−^ mice ([Figure 6](#fig6){ref-type="fig"}A,B), thus explaining their residual moderate hyperleptinemia. Remarkably, several weeks after the final tamoxifen dose to reactivate Arc*Pomc* expression, the same mice had normalized fat and lean mass and a fat/lean mass ratio. In contrast, the non-rescued Arc*Pomc*^−/−^ mice quickly reverted to a higher fat mass and fat/lean mass ratio after being allowed to feed ad libitum.

In addition to normalizing food intake, body weight, body composition, and leptin sensitivity, Arc*Pomc* reactivation in weight-reduced Arc*Pomc*^−/−^ mice corrected their hyperinsulinemia ([Figure 7](#fig7){ref-type="fig"}A) in contrast to the partial reduction observed previously in identically aged, obese Arc*Pomc*^−/−^;*CAG*-Cre-ERT mice treated with tamoxifen [@bib17]. Obese, insulin-resistant Arc*Pomc*^−/−^ mice have paradoxically improved, not worsened, glucose tolerance because of their reduced renal threshold for glycosuria relative to their Arc*Pomc*^+/+^ littermates [@bib37]. Therefore, Arc*Pomc*-rescue actually caused a deterioration of glucose tolerance along with decreased glycosuria to control levels ([Figure 7](#fig7){ref-type="fig"}B,C and [Supplemental Table 1](#appsec1){ref-type="sec"}), presumably due to restoration of renal sympathetic nervous system activity.

3.6. Long-acting PASylated leptin administration prevents normalization of impaired energy balance {#sec3.6}
--------------------------------------------------------------------------------------------------

To examine whether the reduction in hyperleptinemia between obese and calorie restricted Arc*Pomc*^−/−^ mice influenced the efficacy of Arc*Pomc* reactivation to restore a normal body weight set point, we performed a second longitudinal experiment using an additional cohort of 5 to 6-month old male mice ([Figure 8](#fig8){ref-type="fig"}A). One group of calorie restricted Arc*Pomc*^−/−^;*Pomc*-Cre-ERT2 mice was treated with PASylated leptin, a modified form of leptin with extended plasma half-life [@bib34], [@bib35]. The dose was chosen to mimic the extreme hyperleptinemia of obese Arc*Pomc*^−/−^ mice ([Figure 5](#fig5){ref-type="fig"}A) and indeed the treatment raised plasma leptin levels to 95 ± 1 ng/ml prior to the first tamoxifen injection and 90 ± 6 ng/ml following the last tamoxifen injection. A second group of calorie restricted Arc*Pomc*^−/−^;*Pomc*-Cre-ERT2 mice was treated with saline vehicle and their leptin levels were 15 ± 3 and 17 ± 4 ng/ml measured at the same two time points as the PASylated leptin treated group. Two other groups of non-calorie restricted obese Arc*Pomc*^−/−^ mice, one with the *Pomc*-Cre-ERT2 transgene and one without, and a group of lean Arc*Pomc*^+/+^;*Pomc*-Cre-ERT2 control mice were used for comparison. All five groups of mice received the identical tamoxifen treatment.

The obese Arc*Pomc*^−/−^ mice were not affected by tamoxifen and continued to gain weight while the obese Arc*Pomc*^−/−^;*Pomc*-Cre-ERT2 mice had a rapid decrease in weight over two weeks and then stabilized at a level 60% less than their initial weight, but still significantly higher than age-matched control mice. These two groups replicated our previously published findings [@bib17] using the *CAG*-Cre-ERT transgenic driver line. PASylated leptin administration, bookending the tamoxifen injections, prevented the normalization of body weight, body composition, and food intake, while each of these parameters was normalized in the saline- and tamoxifen-treated, calorie restricted group to levels indistinguishable from the Arc*Pomc*^+/+^ mice ([Figure 8](#fig8){ref-type="fig"}B--E). Moreover, the PASylated leptin treated mice actually regained 30% of their lost weight. Their final body weights, fat mass, plasma leptin levels, and food intake were almost the same as those of the group of non-calorie restricted obese Arc*Pomc*^−/−^;*Pomc*-Cre-ERT2 mice 6 wk following tamoxifen administration ([Figure 8](#fig8){ref-type="fig"}B--E).

Next, we assessed hypothalamic *Pomc* mRNA levels by qRT-PCR in the five experimental groups, 6 wk after tamoxifen treatment ([Figure 8](#fig8){ref-type="fig"}F). *Pomc* expression from the reactivated Arc*Pomc*^−/−^ alleles in the calorie restricted Arc*Pomc*^−/−^;*Pomc*-Cre-ERT2 mice was not different from that of the control Arc*Pomc*^+/+^ mice; whereas it was significantly attenuated in both the obese Arc*Pomc*^−/−^;*Pomc*-Cre-ERT2 group and the calorie restricted PASylated leptin treated group following tamoxifen administration ([Figure 8](#fig8){ref-type="fig"}F). The relative levels of hypothalamic *Pomc* mRNA correlated inversely with the measured physiological parameters for each group, suggesting that the former are responsible for the latter.

The specificity of *Pomc* rescue in the hypothalamus of Arc*Pomc*^−/−^;*Pomc*-Cre-ERT2 mice 6 wk following tamoxifen treatment was shown by a lack of change in the minimally detectable levels of *Pomc* mRNA by qRT-PCR in the hippocampus and brain stem ([Supplementary Figure 2](#appsec1){ref-type="sec"}) where *Pomc* expression was 20-fold lower than that in the hypothalamus of ArcPomc^+/+^ mice and was not different between genotypes. We have never observed POMC peptide immunoreactivity or *Pomc* mRNA by in situ hybridization in neuronal soma in non-hypothalamic areas of adult mice despite the fact that *Pomc*-reporter genes often exhibit expression in the brain stem, hippocampus, and amygdala in addition to the Arc [@bib47], [@bib48], [@bib49].

4. Discussion {#sec4}
=============

In this study, we report a direct reciprocal role of hypothalamic POMC and leptin sensitivity in the defense of body weight and adiposity at a given level. Maximal expression of *Pomc* requires a sensitive leptin signaling pathway to normalize body weight and fat composition and leptin requires POMC to induce its anorectic activity. We found that normal body weight can be restored in aged obese Arc*Pomc*^−/−^ mice only if Arc*Pomc* expression is reinstated after plasma leptin is first reduced below a threshold level by calorie restriction. This observation explains why normal body weight could not be restored in our previous study [@bib17] after reactivation of Arc*Pomc* in obese 6-month old Arc*Pomc*^−/−^ mice, which have significantly higher plasma leptin levels relative to calorie-restricted weight-matched mice ([Figure 5](#fig5){ref-type="fig"}A). Therefore, findings from this study support the significance of chronic calorie-restriction [@bib1] and, therefore, relatively lower plasma leptin levels in improving the efficiency of clinical interventions to treat obesity. Our data are also consistent with a recent clinical study that showed significant indirect correlations between cerebrospinal fluid (CSF) levels of POMC and BMI, body fat percentage, CSF leptin, and plasma leptin and insulin [@bib50].

Arc*Pomc*^−/−^ mice, whether obese or weight-matched, with or without a history of obesity, showed no change in food intake and body weight in response to exogenous leptin treatment. These results indicate the necessary role of Arc*Pomc* in mediating the effects of leptin on food intake and body weight. While previous animal studies [@bib43], [@bib45] and clinical observations demonstrate that leptin therapy does not effectively reduce weight in obese subjects [@bib51], we show that leptin treatment is also ineffective in weight-matched mice that lack *Pomc* in the hypothalamus. Since weight-matched *Mc4r*^−/−^ mice do respond to leptin treatment [@bib28], it is possible that the blunted leptin action observed in weight-matched Arc*Pomc*-deficient mice is due to a lack of MC3R signaling by melanocortin activation [@bib21]. Moreover, a recent study [@bib29] reported that while endogenous leptin sensitivity is intact in a diet-induced obesity mouse model, obese *Mc4r*^−/−^ mice do not respond to endogenous leptin, indicating a critical function of the melanocortin system in mediating leptin action during obesity. Altogether, our data support previous observations [@bib21], [@bib28], [@bib29], [@bib30], [@bib43], [@bib52] that melanocortin signaling integrates leptin-mediated effects on energy balance. Our study extends those observations by identifying *Pomc* expression in the Arc, but not pituitary or hindbrain, as the primary mediator of the actions of leptin to reduce food intake and body weight because Arc*Pomc*-deficient mice have normal *Pomc* expression in the pituitary and nucleus tractus solitarius [@bib17], [@bib53]. Chronic hyperleptinemia or increased leptin signaling itself contributes to the attenuated ability of leptin to reduce food intake and body weight [@bib54], [@bib55]; nevertheless, in this study, hyperleptinemia is attributable to increased fat mass due to Arc*Pomc*-deficiency even in the absence of hyperphagia in calorie-restricted mice, a feature that is analogous to *Mc3r*^−/−^ mice [@bib21], [@bib56], [@bib57].

In our previous report [@bib17], we did not measure plasma leptin levels or leptin sensitivity serially in Arc*Pomc*^−/−^ mice. Moreover, it was unclear if the restoration of normal body weight by early, but not delayed, genetic Arc*Pomc* reactivation was associated with restoration of leptin sensitivity. To clarify the role of hypothalamic POMC in leptin sensitivity, we measured plasma leptin levels, and food intake and body weight response after leptin administration in Arc*Pomc*^−/−^ mice. Interestingly, we found that both obese and weight-matched Arc*Pomc*^−/−^ mice exhibited hyperleptinemia. However, the weight-matched mice had significantly lower plasma leptin levels compared to the obese mice. This reduction in leptin apparently contributed to the restoration of normal weight after Arc*Pomc* reactivation in the weight-matched but not obese mice. Both obese and weight-matched Arc*Pomc*-deficient mice did not decrease food intake or body weight in response to exogenous leptin. Remarkably, hyperleptinemia and leptin resistance were corrected after restoration of Arc*Pomc* expression in weight-matched Arc*Pomc* reactivatable mice. These data indicate a direct association of Arc*Pomc* levels with the effects of leptin to reduce food intake and body weight. The longitudinal study also explains why our previous rescue of Arc*Pomc* expression in weight-matched Arc*Pomc*^−/−^;Cre-ERT mice at age 8 wk [@bib17] permanently maintained their body weight and food intake at normal levels with free access to chow. The prevention of obesity by Arc*Pomc* rescue appears to be linked with relatively lower plasma leptin levels or degree of adiposity compared to massively obese mice at the time of Arc*Pomc* reactivation. This observation suggests a critical threshold of plasma leptin levels during which obesity can be normalized by therapeutic interventions; in contrast, if the leptin levels are higher than the threshold, therapeutic interventions might not completely restore bodyweight as observed by us previously in Arc*Pomc^−/−^*;Cre-ERT mice [@bib17].

The increased ratio of fat mass to lean mass with normal body weight in the weight-matched Arc*Pomc*^−/−^ mice is reminiscent of the phenotype of *Mc3r*^−/−^ mice, which have higher fat mass and hyperleptinemia without hyperphagia or hypometabolism [@bib56], [@bib57]. These data confirm that the central melanocortin system directly regulates adiposity, independently of body weight [@bib58]. Remarkably, plasma leptin levels, leptin sensitivity, adiposity, and the ratio of fat mass to lean mass were all corrected after restoration of Arc*Pomc* expression ([Figure 5](#fig5){ref-type="fig"}, [Figure 6](#fig6){ref-type="fig"}) in otherwise Arc*Pomc*-deficient aged mice that had a history of massive obesity. Therefore, our data indicate that energy balance derangements in Arc*Pomc*^−/−^ mice are not attributable to any developmental or compensatory changes that might have occurred due to lifelong hypothalamic *Pomc*-deficiency because the derangements were completely reversed after a combination of prior weight loss by calorie restriction followed by Arc*Pomc*-rescue in obese adult mice.

To further clarify the role of baseline leptin levels in influencing the efficiency of genetic intervention to reverse obesity, we treated calorie restricted reactivatable Arc*Pomc*^−/−^ mice with PASylated leptin [@bib34], which was previously shown to reverse obesity in leptin-deficient *ob*/*ob* mice [@bib35]. Remarkably, the long-acting leptin treatment prevented maximal rescue of Arc*Pomc* expression and its associated phenotype. Similarly, maximal rescue of *Pomc* expression was impaired in obese reactivatable ArcPomc^−/−^ mice that have severe endogenous hyperleptinemia. In strong contrast, calorie restricted reactivatable ArcPomc^−/−^ mice not treated with PASylated leptin exhibited a normal metabolic phenotype and reprogramming of their body weight set point after restoration of Arc*Pomc* expression.

In summary, we have demonstrated that Arc*Pomc*-deficiency increases fat mass and the ratio of fat to lean mass, and it impairs the function of leptin to reduce body weight and food intake independently of body weight. Therefore, rescue of Arc*Pomc* expression in weight-matched Arc*Pomc*^−/−^ mice, whether or not there is a history of previous obesity, reestablishes normal energy homeostasis and body weight set point under ad libitum feeding conditions by correcting the abnormal body composition and restoring leptin sensitivity. In contrast, massive hyperleptinemia induced by PASylated leptin administration prevents this normalization by blocking the complete restoration of Arc*Pomc* expression. Therefore, our study reveals a strong reciprocal association between leptin levels and hypothalamic POMC in the regulation of energy homeostasis that is potentially relevant to explain the high recidivism rate for obesity after dieting that is commonly seen in clinical situations. Moreover, our data suggest that reversal of leptin resistance specifically on hypothalamic POMC neurons is a testable mechanism to explain the clinical findings that high dose leptin therapy is effective at maintaining weight loss after calorie restriction and reduction of endogenous leptin, but not for the primary treatment of obesity [@bib2]. Collectively, our study demonstrates that the interaction between hypothalamic leptin sensitivity and *Pomc* gene expression regulates body weight set point, a phenomenon that can be applied to control obesity more efficiently than targeting either the leptin or POMC signaling pathways alone.
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The following are the supplementary data related to this article:Supplemental Table 1Glycosuria measured with urine glucose test strips during OGTT.Supplemental Table 1Supplemental Figure 1Altered body composition is the earliest detected metabolic phenotype in Arc*Pomc*^−/−^ mice. A) Body weight, B) Fat mass determined by NMR, C) Lean mass determined by NMR, D) Percentage of fat mass relative to body mass, E) Percentage of lean mass relative to body mass, and F) Ratio of lean to fat mass in female Arc*Pomc*^−/−^ (n = 8) and combined littermate Arc*Pomc*^+/+^ (3) and Arc*Pomc*^+/−^ (n = ) mice at ages 3--6 wk. Two-way ANOVAs revealed significant main effects of genotype for each dependent variable (F~1,55~ = 16.9, *P* = 0.0001; F~1,55~ = 39.2, *P* \< 0.0001; F~1,55~ = 7.4, *P* = 0.0089; F~1,55~ = 57.2, *P* \< 0.0001; F~1,55~ = 17.5, *P* = 0.0001; and F~1,55~ = 31.6, *P* \< 0.0001, respectively). \**P* \< 0.05, \*\**P* \< 0.01, \*\*\**P* \< 0.005, and \*\*\*\**P* \< 0.0001; Sidak\'s post-hoc multiple comparisons tests. Data shown are the mean ± SEM.Supplemental Figure 1Supplemental Figure 2Relative *Pomc* mRNA levels in the hippocampus and brain stem (n = 4--6), \*\*\*\**P* \< 0.0001 vs. Arc*Pomc*^+/+^ hypothalamus, Dunnett\'s multiple comparisons test following 1-way ANOVA (F~4,17~ = 253, *P* \< 0.0001, main effect of group). Data shown are the mean ± SEM.Supplemental Figure 2
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![Altered body composition is the earliest detected metabolic phenotype in Arc*Pomc*^−/−^ mice. A) Body weight, B) Fat mass determined by NMR, C) Lean mass determined by NMR, D) Percentage of fat mass relative to body mass, E) Percentage of lean mass relative to body mass, and F) Ratio of lean to fat mass in male Arc*Pomc*^−/−^ (n = 12) and combined littermate Arc*Pomc*^+/+^ (n = 4) and Arc*Pomc*^+/−^ (n = 3) mice at ages 3--6 wk. \**P* \< 0.05, \*\**P* \< 0.01, \*\*\**P* \< 0.005, and \*\*\*\**P* \< 0.0001; Sidak\'s post-hoc multiple comparisons tests. Data shown are the mean ± SEM.](gr1){#fig1}

![Elevated plasma leptin levels and leptin insensitivity of calorie restricted Arc*Pomc*^−/−^ mice weight-matched to Arc*Pomc*^+/+^ mice. A) Plasma leptin levels of 4 to 6-wk old female mice; \*\*\**P* \< 0.005, Student\'s 2-tailed t-test; n = 6. B) Plasma leptin levels of 8-wk old combined male and female mice; \*\*\**P* \< 0.005, Student\'s 2-tailed t-test; n = 6. C) Changes in bodyweight of 16-wk old male mice during 14-day sc leptin or saline infusions from osmotic mini-pumps; \*\*\*\**P* \< 0.0001, leptin vs. saline treated Arc*Pomc*^+/+^ mice (n = 4--8) at day 14, Bonferroni\'s multiple comparisons test following two-way RMANOVA (F~39,221~ = 39, *P* \< 0.0001, interaction of time and treatment). D) Food intake for days 5 and 10 during leptin or saline infusion; \*\**P* \< 0.01, \*\*\**P* \< 0.005, for leptin vs. saline treated Arc*Pomc*^+/+^ mice; ^\#\#^*P* \< 0.01, ^\#\#\#\#^*P* \< 0.0001, for saline and leptin treated Arc*Pomc*^*−*/*−*^ vs. saline treated Arc*Pomc*^+/+^ mice (n = 6), Bonferroni\'s multiple comparisons tests following 2-way ANOVAs (F~3,15~ = 71.6, *P* \< 0.0001, main effect of group at day 5; F~3,15~ = 29.2, *P* \< 0.0001, main effect of group at day 10). Data shown are the mean ± SEM.](gr2){#fig2}

![Central leptin insensitivity of calorie restricted Arc*Pomc*^−/−^ mice weight-matched to Arc*Pomc*^+/+^ mice. A) Changes in bodyweight and B) 24-h food intake of 8-wk old male and female mice after acute central leptin or saline treatment (three icv injections, 5 p.m., 12 a.m., 8 a.m.); \*\*\*\**P* \< 0.0001 for leptin vs. saline treated Arc*Pomc*^+/+^ mice (n = 6), Bonferroni\'s multiple comparisons tests following 2-way ANOVAs (F~3,15~ = 78.3, *P* \< 0.0001, main effect of group for male body weight change; F~3,15~ = 37.3, *P* \< 0.0001, main effect of group for female body weight change; F~3,15~ = 37.2, *P* \< 0.0001, main effect of group for male food intake; and F~3,15~ = 72.9, *P* \< 0.0001, main effect of group for female food intake). Data shown are the mean ± SEM.](gr3){#fig3}

![Reactivation of hypothalamic *Pomc* expression in Arc*Pomc*^−/−^;CreERT mice following chronic calorie restriction normalizes food intake and body weight. A) Time line and experimental design of the longitudinal study. Obese mice were 5 to 6-months old at the start of calorie restriction (Time = 0-wk). B) Schematic showing the insertion of a loxP-flanked neomycin (neo) resistance cassette into the upstream flanking region of the *Pomc* gene to generate the Arc*Pomc*^−^ allele (top). The asterisk indicates the deletion of neural *Pomc* enhancer 2 (nPE2). Deletion of the neo cassette by a tamoxifen-inducible Cre transgene produces the reactivated *Pomc* allele containing nPE1, which is sufficient to drive hypothalamic expression of the gene [@bib18] (bottom). C) Serial body weights at the indicated time points, \*\*\*\**P* \< 0.0001 for Arc*Pomc*^*−*/*−*^ vs. Arc*Pomc*^+/+^;Cre-ERT and Arc*Pomc*^−/−^;Cre-ERT at 24 wk for male (n = 6--13) and female mice (n = 4--7), Bonferroni\'s multiple comparisons tests following 2-way RMANOVAs (F~46,575~ = 69.5, *P* \< 0.0001, interaction of time and male genotype; F~46,322~ = 161, *P* \< 0.0001, interaction of time and female genotype). D) Ad libitum food intake 2 wk after tamoxifen administration, ^\#\#\#\#^*P* \< 0.0001 for Arc*Pomc*^*−*/*−*^ vs. Arc*Pomc*^+/+^;Cre-ERT and Arc*Pomc*^−/−^;Cre-ERT for both males (n = 10--17) and females (n = 9--16), Tukey\'s multiple comparisons test following 1-way ANOVAs (F~2,36~ = 223, *P* \< 0.0001, main effect of male group; F~2,32~ = 127, *P* \< 0.0001, main effect of female group). Data shown are the mean ± SEM. For simplicity, Arc*Pomc*^−/−^;Cre-ERT is used as a common annotation for Arc*Pomc*^−/−^;*CAG*-Cre-ERT and Arc*Pomc*^−/−^;*Pomc*-Cre-ERT2 compound mice.](gr4){#fig4}

![Serial plasma leptin levels and functional measurements of leptin sensitivitity in Arc*Pomc*^−/−^;CreERT mice. A) Serial plasma leptin levels at the indicated experimental stages; \*\*\*\**P* \< 0.0001, Arc*Pomc*^+/+^;Cre-ERT vs. Arc*Pomc*^*−*/*−*^ and Arc*Pomc*^−/−^;Cre-ERT and ^\#\#\#\#^*P* \< 0.0001 for Arc*Pomc*^*−*/*−*^ vs. Arc*Pomc*^+/+^;Cre-ERT and Arc*Pomc*^−/−^;Cre-ERT for males (n = 6--10) and females (n = 8--10), Tukey\'s multiple comparisons tests following separate 1-way ANOVAs for each combination of sex and experimental stage. B) 24-h changes in body weight and C) Absolute 24-h food intake after i.p. leptin treatment at the indicated experimental stages; \*\*\*\**P* \< 0.0001, ^∗∗∗^*P* \< 0.005 for leptin vs. saline treated Arc*Pomc*^+/+^;Cre-ERT for both sexes; ^\#\#\#\#^*P* \< 0.0001, ^\#\#\#^*P* \< 0.005 for leptin vs. saline treated Arc*Pomc*^−/−^;Cre-ERT for both sexes, paired 2-tailed Student\'s t-tests, n = 5--8. Data shown are the mean ± SEM. WM, weight matched; Post-TAM, post-tamoxifen. For simplicity, Arc*Pomc*^−/−^;Cre-ERT is used as a common annotation for either Arc*Pomc*^−/−^;CAG-Cre-ERT or Arc*Pomc*^−/−^;*Pomc*-Cre-ERT2 compound mice.](gr5){#fig5}

![Reactivation of hypothalamic *Pomc* expression in Arc*Pomc*-deficient mice following chronic calorie restriction permanently normalizes body composition. A) Fat mass and B) Lean mass as percentages of body mass; \*\*\*\**P* \< 0.0001 for Arc*Pomc*^+/+^;Cre-ERT vs. Arc*Pomc*^*−*/*−*^ and Arc*Pomc*^−/−^;Cre-ERT for both male and female mice; ^\#\#\#\#^*P* \< 0.0001, for Arc*Pomc*^*−*/*−*^ vs. Arc*Pomc*^−/−^;Cre-ERT and Arc*Pomc*^+/+^;Cre-ERT for both male (n = 4--8) and female (n = 6--7) mice post-tamoxifen, Tukey\'s multiple comparisons tests following 1-way ANOVAs for each combination of sex and experimental stage. Data shown are the mean ± SEM. Post-TAM, post-tamoxifen. For simplicity, Arc*Pomc*^−/−^;Cre-ERT is used as a common annotation for either Arc*Pomc*^−/−^;*CAG*-Cre-ERT or Arc*Pomc*^−/−^;*Pomc*-Cre-ERT2 compound mice.](gr6){#fig6}

![Normalization of glucose homeostasis in Arc*Pomc*-rescue mice. A) Plasma insulin levels, ^\#\#\#\#^*P* \< 0.0001 for Arc*Pomc*^*−*/*−*^ vs. Arc*Pomc*^−/−^;Cre-ERT and Arc*Pomc*^+/+^;Cre-ERT mice, Tukey\'s multiple comparisons test following 1-way ANOVA, n = 6. B) Oral glucose tolerance test (OGTT) and C) corresponding area under the curve (AUC), ^\#\#\#\#^*P* \< 0.0001 for Arc*Pomc*^*−*/*−*^ vs. Arc*Pomc*^−/−^;Cre-ERT and Arc*Pomc*^+/+^;Cre-ERT mice, Tukey\'s multiple comparisons test following 1-way ANOVA, n = 6.](gr7){#fig7}

![PASylated leptin treatment prevents the normalization of metabolic state in calorie restricted male Arc*Pomc*^−/−^ mice. A) Body weight for each of the five groups of mice over 12 wk. A 2-way RMANOVA for all groups, except Arc*Pomc*^−/−^, from weeks 9--12 revealed a significant interaction of time and group (F~9,42~ = 4.3, *P* \< 0.001). B) Final body weight, C) Food intake, D) Fat mass, E) Plasma leptin levels, and F) Hypothalamic *Pomc* mRNA levels. N = 4--6, \*\**P* \< 0.01, \*\*\**P* \< 0.005, and \*\*\*\**P* \< 0.0001 vs. Arc*Pomc*^+/+^;*Pomc*-Cre-ERT mice, Dunnett\'s multiple comparisons test following 1-way ANOVAs for each measurement. CR, calorie restriction; TAM, tamoxifen; PAS-leptin, PASylated leptin. Data shown are the mean ± SEM.](gr8){#fig8}
